Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients

Status Recruiting

Clinical Trial Summary

This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. All patients enrolled must have a mitogen-activated protein kinase (MAPK) activating mutation to be deemed eligible for trial participation. Each disease-based basket will open to enrollment in two-stages. The opening of stage two will be dependent on the observed responses in the patients enrolled in the first stage.

Clinical Trial Description

This is an open-label, multicenter, phase II basket study of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring rat sarcoma virus (RAS), a member of the rapidly accelerated fibrosarcoma (non-V600 BRAF), extracellular signal-regulated kinase (ERK), or mitogen-activated protein kinase (MEK) mutations. The trial will have five baskets based on disease primary as listed below. Basket 1: Cholangiocarcinoma including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, or extrahepatic cholangiocarcinoma; Basket 2: Pancreatic adenocarcinoma; Basket 3: Colorectal adenocarcinoma; Basket 4: Esophageal adenocarcinoma, esophageal squamous cell carcinoma, or gastroesophageal junction (GEJ) adenocarcinoma; Basket 5: Gastric adenocarcinoma. While the overall trial is a basket design, each basket will operate as a Simon two-stage design and therefore, will open to enrollment in two-stages. Total enrollment for Stage 1 is targeted at approximately 65 patients with 13 patients per group. Additional patients may be enrolled as appropriate. Total enrollment for Stage 2 is targeted to approximately 150 patients with up to 30 patients per group. Additional patients may be enrolled as appropriate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05221320
Study type	Interventional
Source	BioMed Valley Discoveries, Inc
Contact	Biomed Valley Discoveries, Inc.
Phone	816-960-6600
Email	ERK@biomed-valley.com
Status	Recruiting
Phase	Phase 2
Start date	May 26, 2022
Completion date	March 19, 2025

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Not yet recruiting	`NCT05044312` - Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis	N/A
Active, not recruiting	`NCT05053191` - Advancing Nursing Practices in Hospital Oncology Care	N/A
Completed	`NCT03611309` - Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members	N/A
Recruiting	`NCT03602677` - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage	N/A
Recruiting	`NCT03190941` - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Phase 1/Phase 2
Not yet recruiting	`NCT06398314` - Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors	N/A
Withdrawn	`NCT04030624` - Remote Electronic Patient Monitoring in Gastrointestinal Cancer	N/A
Completed	`NCT02222259` - A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients	N/A
Completed	`NCT02140593` - The Laparotomy Study	Phase 4
Active, not recruiting	`NCT00716209` - Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers	N/A
Recruiting	`NCT01484444` - Biomarker Analysis of Gastrointestinal Cancer	N/A
Completed	`NCT02130427` - A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy	N/A
Active, not recruiting	`NCT00710632` - Screening to Predict Weight Loss in Patients With Cancer	N/A
Completed	`NCT00094965` - Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function	Phase 2
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Recruiting	`NCT05226221` - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Recruiting	`NCT03286348` - Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms